Back to top
more

Acorda Therapeutics, Inc. (ACOR)

(Delayed Data from NSDQ)

$11.74 USD

11.74
1,452,260

+1.16 (10.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.74 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down

Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.

    Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line

    Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.

      Arpita Dutt headshot

      Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More

      Key highlights in the biotech sector include mixed data from Cara (CARA) and regulatory updates from companies like BioMarin.

        Acorda Files NDA for Parkinson's Disease Candidate Inbrija

        Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.

          Acorda Presents Phase III Data on PD Candidate CVT-301

          Acorda Therapeutics, Inc. (ACOR) presented data from a phase III study SPAN-PD, evaluating its late stage candidate CVT-301 (levodopa inhalation powder) at the International Congress of Parkinson's Disease and Movement Disorders (MDS).

            Why Is Acorda (ACOR) Down 8.4% Since the Last Earnings Report?

            Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Biogen's Fampyra Conditional Approval Converted to Standard

              Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.

                Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss

                Acorda Therapeutics, Inc. (ACOR) reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents.

                  Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline

                  Acorda Therapeutics, Inc. (ACOR) recently announced plans to reduce its workforce by approximately 20%.

                    Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge

                    Acorda Therapeutics, Inc.???s (ACOR) shares were down almost 21.5% after the U.S. District Court for the District of Delaware invalidated four patents of its key multiple sclerosis drug, Ampyra.

                      Acorda Presents Data for Parkinson's Candidate CVT-301

                      Acorda Therapeutics, Inc. (ACOR) announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson's disease.

                        Alkermes Starts Phase III Study to Treat Multiple Sclerosis

                        Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.

                          Why Is Acorda (ACOR) Up 10.6% Since the Last Earnings Report?

                          Acorda Therapeutics (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            Arpita Dutt headshot

                            Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data

                            The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.

                              Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise

                              U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of Acorda's key growth driver, Ampyra.

                                Acorda Therapeutics (ACOR) Jumps: Stock Adds 6.5% in Session

                                Acorda Therapeutics, Inc. (ACOR) moved big last session, as its shares rose above 6% on the day.

                                  Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options

                                  Investors in Acorda Therapeutics, Inc. (ACOR) need to pay close attention to the stock based on moves in the options market lately.

                                    Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4

                                    Acorda Therapeutics, Inc. (ACOR) reported loss of 7 cents per share in the fourth quarter of 2016 (including the impact of stock-based compensation expenses), narrower than the Zacks Consensus Estimate of a loss of 18 cents.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

                                      Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

                                        The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

                                        The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

                                          Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?

                                          Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.

                                            Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?

                                            Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16.

                                              Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?

                                              Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.

                                                Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session

                                                Acorda Therapeutics, Inc. (ACOR) moved big last session, as its shares rose almost 21% on the day.

                                                  Can Prothena (PRTA) Pull a Surprise This Earnings Season?

                                                  Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.